KDR and ovarian carcinoma: Its potential function may hinder glycolysis and angiogenesis in PARPi resistant ovarian cancer cells, which is associated with PS VII binding and stabilizing RORα expression, further inhibiting ECM1 and blocking the VEGFR2/FAK/AKT/GSK3β signaling pathway.